Mission

Rainbow Genomics is a pioneer in the commercialization of next-generation sequencing-based, diagnostic and health screening solutions to individuals in Asia.  

We are committed to providing clinically-validated and evidence-based genetic tests to patients in Asia.  We specialize in providing whole-exome-sequencing, pharmacogenomic, cancer and heart health tests, enabling individuals and their physicians to use genomic information for diagnosis, treatment and disease prevention.  

Coupled with our industry-first "Double Interpretation", provided simultaneously by U.S. and Japanese medical Institutions, we target unique Asian genetics to improve overall diagnostic yield.

Company

Rainbow is both a new product developer and a distributor of U.S.-based genetic assessment applications.

Our market coverage includes pediatric and adult hereditary disorders, pharmacogenomics and common disease risk assessment with clinical utilities.  We understand how to integrate U.S. clinical best practices with localized "product components" to address various market segments.

We co-developed U.S.-based clinical applications with our institutional partners, and deploy credible clinical assessment products through highly-effective channels, to address both the domestic and medical tourism markets in Hong Kong, Japan and other Asian countries

Our management and clinical advisory teams consist of genetics, health care, ethics and public policy experts with substantial research and clinical experience. We have contracted with the following partners & providers to deliver clinically-validated tests following ACMG (American College of Medical Genetics and Genomics) guidelines.

• University of California, Los Angeles (UCLA) Clinical Genomics Center 
• Baylor Genetics (Baylor)
• Consultagene from Baylor College of Medicine
• OneOme (established by Invenshure and Mayo Clinic)
• Color Genomics
• Jundento University, Center for Intractable Disease Research and Medical School, Japan
• Multiple CAP (College of American Pathologists)-accredited and CLIA (Clinical Laboratory Improvement Amendments)-certified DNA sequencing laboratories

Our Tests

" Physician Reports Issued By U.S. Board-Certified Medical Directors"

Most of our genetic tests are based on clinical whole-exome-sequencing technology.   

To assure highly accurate test results, DNA sequencing is performed at CAP-accredited or CLIA-certified laboratories.  

Data analysis and clinical interpretation are performed by the UCLA Clinical Genomics Center and Baylor Genetics, both are among the largest and oldest genetic testing laboratories in the U.S. Their board-certified medical directors will issue physician reports. 

We also work closely with OneOme, a U.S. company established by Invenshure and Mayo Clinic, to provide a comprehensive pharmacogenomic test covering over 340 medications.  

Our "preferred" partnership with U.S.-based Color Genomics enables us to provide affordable hereditary cancer and heart health tests to middle class patients who otherwise could not afford to be tested.

In addition, we partner with Consultagene from Baylor College of Medicine to provide genetic counseling to patients, and peer-to-peer consultation to physicians.